. 2019 Sep 7;25(33):4970–4984. doi: 10.3748/wjg.v25.i33.4970

Table 6.

Univariate and multivariate analyses of risk factors for oncological outcomes in both emergency surgery and bridge to surgery groups

3-year disease-free survival	*ES group (n =* 56)**				*BTS group (n =* 32)**
3-year disease-free survival	Univariate		Multivariate		Univariate		Multivariate
Characteristic	HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value
CEA (≥ 5 ng/mL vs <5 ng/mL)	1.71 (0.74-3.95)	0.209			2.67 (0.72-9.90)	0.141
ASA (Grade ≥ III vs Grade < III)	0.890 (0.36-2.23)	0.803			1.49 (0.41-5.43)	0.542
pT stage (pT3-4 vs pT1-2)	2.26 (0.85-6.02)	0.104			2.48 (0.55-11.18)	0.239
pN stage (pN+ vs pN0)	1.48 (0.64-3.43)	0.361			2.48 (0.55-11.18)	0.239
LVI (+) vs LVI (-)	2.92 (1.25-6.81)	0.013			1.97 (0.66-5.88)	0.224
NLR ≥ 19.3 vs NLR < 19.3	2.76 (1.02-7.45)	0.046
dNLR ≥ 1.57 vs dNLR < 1.57	2.85 (1.17-6.95)	0.021	3.02(1.23-7.42)	0.016
PLR ≥ 317 vs PLR < 317	1.55 (0.66-3.67)	0.314
SII ≥ 3645 vs SII < 3645	2.04 (0.86-4.83)	0.104
LMR ≥ 1.67 vs LMR < 1.67					2.54 (0.83-7.80)	0.091	3.11 (1.13-8.54)	0.052
Chemotherapy (+) vs (-)	0.95 (0.41-2.19)	0.896			1.44 (0.47-4.41)	0.523

SEMS: Self-expanding metal stents; BTS: Bridge to surgery; dNLR: Derived neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune inflammation index; LMR: Lymphocyte-to-monocyte ratio; LVI: Lymphovascular invasion. Chemotherapy (+), accept chemotherapy lately. Chemotherapy (-), refuse to chemotherapy lately. P < 0.05 was considered significant.